Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Luminarie","sponsor":"TaiGen Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Out-Licensed Taigexyn\u00ae to Luminarie Canada for Canada, Australia and New Zealand","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Luminarie

    Menu

    Luminarie

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Luminarie

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Out-Licensed Taigexyn® to Luminarie Canada for Canada, Australia and New Zealand

              Details:

              Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.

              Lead Product(s): Nemonoxacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: Taigexyn

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: TaiGen Biotechnology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY